750 related articles for article (PubMed ID: 14618296)
1. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 CYP2D6.
Wolf CR; Smith G
IARC Sci Publ; 1999; (148):209-29. PubMed ID: 10493260
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse C; Brockmöller J; Bauer S; Roots I
Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
Zanger UM; Fischer J; Raimundo S; Stüven T; Evert BO; Schwab M; Eichelbaum M
Pharmacogenetics; 2001 Oct; 11(7):573-85. PubMed ID: 11668217
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
10. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population.
Isaza CA; Henao J; López AM; Cacabelos R
Methods Find Exp Clin Pharmacol; 2000 Nov; 22(9):695-705. PubMed ID: 11294012
[TBL] [Abstract][Full Text] [Related]
11. Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature.
Ito T; Kato M; Chiba K; Okazaki O; Sugiyama Y
Drug Metab Pharmacokinet; 2010; 25(3):243-53. PubMed ID: 20610883
[TBL] [Abstract][Full Text] [Related]
12. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
13. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of genetic polymorphisms of drug metabolism.
Meyer UA; Zanger UM
Annu Rev Pharmacol Toxicol; 1997; 37():269-96. PubMed ID: 9131254
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450: genetic polymorphism and drug interactions.
Belpaire FM; Bogaert MG
Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
17. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.
Thuerauf N; Lunkenheimer J
Eur Arch Psychiatry Clin Neurosci; 2006 Aug; 256(5):287-93. PubMed ID: 16783493
[TBL] [Abstract][Full Text] [Related]
18. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 polymorphisms and the impact on tamoxifen therapy.
Beverage JN; Sissung TM; Sion AM; Danesi R; Figg WD
J Pharm Sci; 2007 Sep; 96(9):2224-31. PubMed ID: 17518364
[TBL] [Abstract][Full Text] [Related]
20. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]